You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 138 No. 11, November 1984 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (34)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Pneumocystis carinii Pneumonitis

A Comparative Trial of Sulfamethoxazole-Trimethoprim v Pentamidine in Pediatric Patients With Cancer: Report From the Childrens Cancer Study Group

Stuart E. Siegel, MD; Lawrence J. Wolff, MD; Robert L. Baehner, MD; Denman Hammond, MD

Am J Dis Child. 1984;138(11):1051-1054.


Abstract



• Pentamidine isethionate and sulfamethoxazole-trimethoprim are effective in the treatment of Pneumocystis carinii pneumonia in the immunosuppressed pediatric patient. To compare their efficacy and toxicity, 25 pediatric cancer patients with biopsy-proved P carinii pneumonia were randomly assigned to receive either pentamidine intramuscularly or sulfamethoxazole-trimethoprim orally for 14 days. No differences in response or frequency of side effects were noted between the two drug regimens, with recovery occurring in 24(96%) of 25 children. Skin eruptions and hematologic abnormalities were the most common side effects of sulfamethoxazole-trimethoprim therapy, while local reactions at injection sites, abnormal renal function, and hypoglycemia were the most frequent complications of pentamidine treatment. The ease of administration and less serious side effects of sulfamethoxazole-trimethoprim make it the drug of first choice for treating P carinii pneumonia. Pentamidine remains an important drug for patients who fail to respond to this initial therapy.

(AJDC 1984;138:1051-1054)



Author Affiliations



From the Childrens Cancer Study Group, Los Angeles.


Footnotes



Reprint requests to Childrens Cancer Study Group Operations Office, 1721 Griffin Ave, Los Angeles, CA 90031 (Dr Siegel).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evolving Health Effects of Pneumocystis: One Hundred Years of Progress in Diagnosis and Treatment
Kovacs and Masur
JAMA 2009;301:2578-2585.
ABSTRACT | FULL TEXT  

Trimethoprim-Sulfamethoxazole or Pentamidine for Pneumocystis carinii Pneumonia
BEGIN and HANLEY
ANN INTERN MED 1987;106:474-476.
ABSTRACT  

Trimethoprim-Sulfamethoxazole or Pentamidine for Pneumocystis carinii Pneumonia in the Acquired Immunodeficiency Syndrome: A Prospective Randomized Trial
WHARTON et al.
ANN INTERN MED 1986;105:37-44.
ABSTRACT  

Pentamidine for the Treatment of Pneumocystis carinii Pneumonia and Other Protozoal Diseases
PEARSON and HEWLETT
ANN INTERN MED 1985;103:782-786.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.